Snapshot from Jul 26, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Teva-Polpharma Ocrevus biosimilar...
Business licensing agreement

Teva-Polpharma Ocrevus biosimilar licensing deal

Analysis based on 14 articles · First reported Jul 09, 2026 · Last updated Jul 09, 2026

Sentiment
15
Attention
3
Articles
14
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The agreement strengthens Teva's biosimilars pipeline and commercial prospects, potentially boosting its stock. Polpharma Biologics gains a global commercialization partner, enhancing its revenue potential.

Pharmaceuticals Biotechnology
Event Summary

Sun Pharma Ltd, through its subsidiary Teva Pharmaceuticals International GmbH, and Polpharma Biologics International AG announced a global licensing agreement on July 9, 2026. Under the agreement, Teva secures exclusive rights to commercialize Polpharma Biologics' biosimilar candidate to Ocrevus (ocrelizumab), including both intravenous and subcutaneous formulations, upon regulatory approval. Polpharma Biologics retains responsibility for development and manufacturing, while Teva handles regulatory submissions and commercialization in the United States, Europe, Brazil, Canada, Australia, New Zealand, Israel, and Turkey. The deal aligns with Teva's Pivot to Growth strategy to expand its biosimilars pipeline. Ocrevus is a registered trademark of F. Hoffmann-La Roche — Genentech, Inc. and/or Roche Ltd, used for treating multiple sclerosis.

Key Actions
90 Sun Pharma secured exclusive rights Polpharma Biologics International AG
90 Polpharma Biologics International AG granted global license Sun Pharma
Entities Involved
stock
Sun Pharma
Teva secures exclusive global rights to commercialize the biosimilar, advancing its Pivot to Growth strategy and expanding its biosimilars pipeline.
Importance 100.0 Sentiment 20.0
priv
Polpharma Biologics International AG
Polpharma Biologics grants Teva a global license, leveraging Teva's commercial footprint while retaining development and manufacturing responsibilities.
Importance 100.0 Sentiment 20.0
cnt
United States
The U.S. is a key market where Teva will commercialize the biosimilar upon approval.
Importance 20.0 Sentiment 0.0
loc
Europe
Europe is a major region for commercialization of the biosimilar.
Importance 20.0 Sentiment 0.0
cnt
Israel
Israel is a commercialization territory and Teva's home country.
Importance 10.0 Sentiment 0.0
subs
F. Hoffmann-La Roche — Genentech
F. Hoffmann-La Roche — Genentech's Ocrevus faces potential biosimilar competition, which may erode market share.
Importance 10.0 Sentiment -10.0
stock
Roche
Roche's Ocrevus franchise may face competition from the biosimilar, potentially impacting revenues.
Importance 10.0 Sentiment -10.0
cnt
Brazil
Brazil is included in the commercialization territories for the biosimilar.
Importance 10.0 Sentiment 0.0
cnt
Canada
Canada is part of the commercialization territories.
Importance 10.0 Sentiment 0.0
cnt
Australia
Australia is included in the commercialization territories.
Importance 10.0 Sentiment 0.0
per
Anjan Selz
As CEO of Polpharma Biologics, Anjan Selz announced the agreement, highlighting the collaboration.
Importance 5.0 Sentiment 0.0
per
Yolanda Tibbe
As Vice President, Global Head of Biosimilars at Teva, Yolanda Tibbe commented on the strategic alignment.
Importance 5.0 Sentiment 0.0
cnt
New Zealand
New Zealand is part of the commercialization territories.
Importance 5.0 Sentiment 0.0
cnt
Turkey
Turkey is included in the commercialization territories.
Importance 5.0 Sentiment 0.0
Relationships
Sun Pharma related ↔ United States
United States strategic ally ↔ Israel The United States acts as the primary military and diplomatic patron for Israel, supplying billions in arms and joint op
United States related ↔ Roche
United States related ↔ Brazil
United States strained-ally ↔ Canada The United States has severely strained its historically close relationship with Canada by imposing sweeping tariffs and
United States related ↔ Australia
Israel related ↔ Brazil
Israel related ↔ Canada
Israel related ↔ Australia
F. Hoffmann-La Roche — Genentech related ↔ Roche
Brazil related ↔ Canada
Brazil related ↔ Australia
Canada related ↔ Australia
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.